Author:
Akkahadsee Pattaraporn,Sawangjit Ratree,Phumart Panumart,Chaiyakunapruk Nathorn,Sakloetsakun Duangkamon
Abstract
AbstractAnti-tuberculosis drug induced liver injury (Anti-TB DILI) is the most common adverse events (AEs) necessitating therapy interruption but there is no preventing regimen. This study aimed to examine the efficacy and safety of herbs/alternative medicines for preventing anti-TB DILI. Relevant articles were identified through a systematic search in 5 international databases from inception till March 2022. All randomized controlled trials (RCT) assessing the effects of herbal or alternative medicines against anti-TB DILI were included. The network meta-analysis (NMA) was used to synthesize the evidence for preventing hepatotoxicity using a random-effects model. A total of 3423 patients from 14 RCTs were included. The NMA indicated that supplementation of Turmeric plus Tinospora cordifolia (RR 0.07; 95% CI 0.02 to 0.28), and N-acetyl cysteine (NAC) (RR 0.09; 95% CI 0.01 to 0.75) significantly reduced the incidence of anti-TB DILI compared with placebo. In addition, poly herbal product significantly reduced alkaline phosphatase (ALP) (MD − 21.80; 95% CI − 33.80 to − 9.80) and total bilirubin (Tbil) compared with placebo (MD − 0.51; 95% CI − 0.76 to − 0.26). There was no statistically significant difference in the occurrence of AEs in any intervention. In conclusion, Turmeric plus Tinospora cordifolia, NAC and poly-herbal product may provide benefit for preventing anti-TB DILI in TB patients. However, these findings are based on a small number of studies. Additional studies are warranted to confirm the findings.
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Dolin, P. J., Raviglione, M. C. & Kochi, A. A Review of Current Epidemiological Data and Estimation of Future Tuberculosis Incidence and Mortality (Springer, 1993).
2. WHO. Global tuberculosis report 2017.Geneva, Switzerland: World Health Organization. https://reliefweb.int/report/world/global-tuberculosis-report-2017?gad_source=1&gclid=CjwKCAiA3aeqBhBzEiwAxFiOBoLL36ip61BFeWsDmhe8pDhuQ1-9kweK_y4uz1QJ8p11VPMSjo1hkhoCmcoQAvD_BwE (2017).
3. Makhlouf, H. A., Helmy, A., Fawzy, E., El-Attar, M. & Rashed, H. A. G. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hep. Intl. 2, 353–360. https://doi.org/10.1007/s12072-008-9085-y (2008).
4. Schaberg, T. The dark side of antituberculosis therapy: Adverse events involving liver function. Eur. Respir. J. 8, 1247–1249. https://doi.org/10.1183/09031936.95.08081247 (1995).
5. Babalik, A. et al. Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks 60, 136–144 (2012).